AIM ImmunoTech, Inc. operates as a biopharmaceutical company, which engages in the clinical development of new drug therapies based on natural immune system enhancing technologies for the treatment of viral and immune based disorders.
Aim Immunotech stock last closed at $9.30, down 2.11% from the previous day, and has increased 2,278.52% in one year. It has overperformed other stocks in the Biotechnology industry by 23.5 percentage points. Aim Immunotech stock is currently +14,661.9% from its 52-week low of $0.06, and -10.58% from its 52-week high of $10.40.
At the moment, there are 764,239 shares of AIM outstanding. The market cap of AIM is $7.11M. In the last 24 hours, 10,100 AIM shares were traded.
You will need a brokerage account to access the NYSEMKT market and buy AIM stock.
Based on our research, eToro is the best brokerage. eToro gives you:
Get $10 towards your purchase of stock by opening an account with eToro today. This offer is only for US users.
Open eToro AccountNow that you've picked your brokerage, you'll need to fill out some personal information so you are able to invest in AIM stock today.
Now that you have created your account on stock apps to use, you need to deposit funds:
Watch the tutorial below if you need help depositing funds into your investment account.
Once you have chosen the best place to buy Aim Immunotech stock, it's absolutely critical to evaluate their stock prior to investing, so you can comprehend the risk as well as the opportunity.
WallStreetZen was created to help average investors do more in-depth fundamental analysis quickly.
You can view all of the due diligence checks on AIM's stock page.
Investors use many financial metrics, analyses, models, and charts to gauge AIM's intrinsic value.
You can access more valuation research on AIM's stock here.
Last year, AIM revenue was $146.00k. In the last five year, AIM's revenue has increased by -4.62% per year. This was slower than the Biotechnology industry average of 42.72%.
You can research AIM's earnings and revenue performance here.
Over the past 12 months, insiders at AIM have bought more shares than they have sold.
Thomas K. Equels, CEO President of AIM, was the latest AIM insider to buy. They bought $823.58 worth of AIM shares on Jun 13, 2025.
Research more about who owns AIM stock here.
No, Aim Immunotech doesn't provide an income stream by paying out dividends.
One of the reasons eToro is our highest-rated brokerage is because of its social trading community.
Click below to learn what other investors have to say.
You have two main order types:
Press the Open Trade button and your broker will execute the order.
If you require additional assistance buying stocks on eToro, click the helpful video below:
Now that you own some AIM shares, you'll want to keep up with your new company.
Add AIM to a watchlist to keep tabs on your AIM stock.
To summarize, here are the 6 steps you need to take to buy Aim Immunotech stock right now:
If you are looking for a online brokerage, eToro is our favorite venue.
Get Started with eToro TodayIf you would like to get the latest news on your new investment in Aim Immunotech, create a watchlist today.